At the #AACR26 press conference,
@OmarNadeemMD
of
@DanaFarber
presents results of the phase 2 CAR-PRISM clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma. The study also published today at
@NatureMedicine
: